Szérum csontmarkerek a gyulladásos bélbetegségekhez társuló csontanyagcsereeltérésekben.

P. Miheller, M. Tóth, E. Molnár, T. Zágoni, K. Rácz, Z. Tulassay

Research output: Article

10 Citations (Scopus)


Patients with inflammatory bowel disease (IBD) have decreased bone mineral density (BMD), which is usually much more remarkable in patients with Crohn's disease (CD) than those with ulcerative colitis (UC). The aim of the present study was to investigate the usefulness of serum beta-Crosslaps (bCL) and osteocalcin (OC) determinations to assess bone metabolism in patients with IBD. Forty-nine patients with IBD (23 UC, 26 CD) and 46 healthy controls were studied. Serum bCL and OC were measured by Elecsys immunoassay. Compared to controls (0.275 +/- 0.14 ng/ml) the mean bCL concentration was significantly higher in the CD (mean = 0.489 +/- 0.25 ng/ml; p < 0.001) and UC groups (mean = 0.439 +/- 0.3 ng/ml; p < 0.01). The mean OC concentration was significantly higher in the CD group (28.52 +/- 14.75 ng/ml) than in controls (21.42 +/- 7.43 ng/ml) but OC level was not significantly increased in the UC group (24.89 +/- 15.08 ng/ml). There was no significant difference in bCL or OC concentrations between the CD and UC groups. These results indicate that the accelerated bone resorption is not associated with increased bone formation in patients with IBD. These two marker of the bone metabolism could be a good laboratory parameter of bone pathology in patients with IBD, especially in CD.

Translated title of the contributionSerum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases
Original languageHungarian
Pages (from-to)1557-1560
Number of pages4
JournalOrvosi hetilap
Issue number29
Publication statusPublished - júl. 22 2001

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Szérum csontmarkerek a gyulladásos bélbetegségekhez társuló csontanyagcsereeltérésekben.'. Together they form a unique fingerprint.

  • Cite this